Importantly and in line with our DYRK1B RNAi data, DYRKi treatment of SAG-treated SUFU-positive (WT MB +SAG) and untreated SUFU-depleted (ΔSufu MB) human medulloblastoma cells prevented GLI1 mRNA expression at comparable IC50 concentrations of 1.16 μM and 1.04 μM, respectively (Figure 4C). This evidence concerns the gene SAG and medulloblastoma.